Hydration Pharmaceuticals Co. Ltd. AI Stock Analysis
Want to see AU:HPC full AI Analyst Report?
Hydration Pharmaceuticals Co. Ltd. (HPC) AI Stock Analysis
Hydration Pharmaceuticals Co. Ltd.
(ASX:HPC)
The score is driven primarily by weak financial performance, especially persistent negative operating/free cash flow and structurally unprofitable operations alongside volatile and declining revenue. Valuation is also challenged by a negative P/E and no dividend yield data. Technical analysis is neutral due to missing indicator data, while the low-debt position in recent years is a partial offset but not enough to outweigh cash burn and profitability issues.
Hydration Pharmaceuticals Co. Ltd. (HPC) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 1.61M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.96
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Australia
- Employees
- 3
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Food Distribution
Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model
Company Description
The Hydration Pharmaceuticals Company Limited, established in 2001, provides a diverse portfolio of healthy hydration remedies, offered as liquids, tablets, and powders. Operating from its headquarters in San Diego, California, the company distribute...
Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview
Summary
Overall fundamentals are weak. The income statement reflects volatile revenue with a sharp decline in 2025 and deeply negative operating profitability, while cash flow is a major concern with consistently negative operating and free cash flow and worsening cash burn in 2025. The main offset is low leverage in 2024–2025 (no reported debt), but equity and assets have been unstable, keeping financial risk elevated.
Income Statement
18Very NegativeBalance Sheet
42NeutralCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.14M | 2.56M | 3.20M | 10.04M | 9.10M | 6.13M |
| Gross Profit | 18.49K | -27.42K | 1.62M | 5.39M | 4.70M | 2.79M |
| EBITDA | -2.71M | -3.26M | 286.28K | 0 | -10.51M | -6.08M |
| Net Income | -2.48M | -2.96M | 2.67M | -8.10M | -10.61M | -8.97M |
Balance Sheet | ||||||
| Total Assets | 1.24M | 2.19M | 5.00M | 6.69M | 10.39M | 15.31M |
| Cash, Cash Equivalents and Short-Term Investments | 442.73K | 1.12M | 3.22M | 1.84M | 4.69M | 10.67M |
| Total Debt | 0 | 0 | 0 | 3.89M | 3.71M | 0 |
| Total Liabilities | 581.54K | 774.76K | 2.25M | 7.05M | 6.41M | 2.08M |
| Stockholders Equity | 656.00K | 1.42M | 2.74M | -358.25K | 3.98M | 13.23M |
Cash Flow | ||||||
| Free Cash Flow | -3.10M | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Operating Cash Flow | -3.10M | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Investing Cash Flow | 0 | 0 | 9.44M | 0 | 0 | -2,151 |
| Financing Cash Flow | 594.36K | 833.93K | -3.63M | 2.72M | 4.08M | 17.03M |
Hydration Pharmaceuticals Co. Ltd. Peers Comparison
Overall Rating
AU:CLV77Outperform
AU:BUB48Neutral
AU:NGS46Neutral
AU:AHF43Neutral- AU:HPC43Neutral
AU:NUC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CLV | 77Outperform | AUD 168.67M | 16.37 | 13.83% | 2.45% | 13.26% | 49.05% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:BUB | 48Neutral | AUD 69.82M | -15.19 | -11.08% | ― | 9.08% | -183.87% |
| AU:NGS | 46Neutral | AUD 20.25M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
| AU:AHF | 43Neutral | AUD 15.39M | -4.47 | -12.90% | ― | 0.46% | 46.48% |
| AU:HPC | 43Neutral | AUD 1.08M | -0.36 | -239.37% | ― | ― | ― |
| AU:NUC | 37Underperform | AUD 9.57M | -1.28 | -88.51% | ― | 11.96% | -81.99% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:HPC | Hydration Pharmaceuticals Co. Ltd. | ― | ― | ― | |
| AU:AHF | Australian Dairy Nutritionals Group | 0.02 | -0.02 | -57.89% | |
| AU:BUB | Bubs Australia Ltd. | 0.08 | -0.08 | -51.25% | |
| AU:NUC | Nuchev Pty Ltd | 0.06 | -0.10 | -63.03% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | 0.00 | 15.79% | |
| AU:CLV | Clover Corporation Limited | 1.02 | 0.36 | 54.78% |
Hydration Pharmaceuticals Co. Ltd. Corporate Events
Hydration Pharmaceuticals Launches Major Pro Rata Capital Raising on ASX
Hydration Pharmaceuticals Company Limited has announced a proposed non-renounceable pro rata issue of new securities to existing shareholders, including up to 358,658,990 ordinary fully paid shares and 179,329,495 options expiring on June 30, 2029 wi...
Hydration Pharmaceuticals Launches Entitlement Offer to Raise Up to $1.43 Million
Hydration Pharmaceuticals Company Limited has launched a non-renounceable pro-rata entitlement offer, allowing existing shareholders to subscribe for two new shares for every three held at an issue price of $0.004, with free-attaching options exercis...
Hydration Pharmaceuticals launches A$1.43m entitlement offer and share sale facility
The Hydration Pharmaceuticals Company Limited has launched a non-renounceable pro rata entitlement offer, allowing eligible shareholders in Australia and New Zealand to subscribe for two new shares for every three held at A$0.004 per share. Each two...
Hydration Pharmaceuticals Shareholders Approve Capital Measures at Extraordinary Meeting
Hydration Pharmaceuticals Company Limited, known as Hydralyte USA, is a hydration solutions company that develops and markets electrolyte-based products for consumer health, with a focus on dehydration management in key markets such as the United Sta...
Hydration Pharmaceuticals Slashes Losses as Hydralyte LLC Turns EBITDA Positive
Hydration Pharmaceuticals reported a sharp turnaround in its mid‑2026 trading, driven by restructuring, tighter cost control and stronger margins in its Hydralyte LLC unit. Across July and August, consolidated EBITDA loss shrank 75% year on year to A...
Hydration Pharmaceuticals Sets Virtual Extraordinary Shareholder Meeting for October
Hydration Pharmaceuticals Co. Ltd. has called an extraordinary general meeting of shareholders to be held virtually at 10:00 a.m. AEST on Thursday, 8 October 2026, via an online platform hosted by its share registry. The notice of meeting and explana...
Hydration Pharmaceuticals Sets Online Extraordinary General Meeting for October 2026
The Hydration Pharmaceuticals Company Limited has called an Extraordinary General Meeting for 8 October 2026, to be held online via Automic’s Investor Portal with a live webcast, enabling shareholders to view proceedings, vote in real time and submit...
Hydration Pharmaceuticals Narrows Half-Year Loss as Net Tangible Assets Turn Positive
Hydration Pharmaceuticals Co. Ltd., trading on the ASX under ticker HPC, operates in the pharmaceutical and health segment with an emphasis on hydration products and related services. The company prepares accounts to Australian standards and maintain...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026